GRI Bio announces two global patents granted for Europe and Japan
Ella Day | April 2, 2025 | News story | Research and Development | Chronic Diseases, GRI Bio, autoimmune diseases, biotech, fibrotic diseases, inflammatory diseases, patent
GRI Bio, a biotech company that specialises in treatment for inflammatory, fibrotic and autoimmune diseases, has announced that two global patents have been granted in Europe and Japan.
The first is a European patent titled, ‘Oxygenated Amino- or Ammonium Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use.’ It aims to cover GRI-0803, which is the company’s activator of human type 2 diverse Natural Killer T (NKT) cells for the treatment of autoimmune disorders.
Secondly, the Japan patent titled, ‘Prevention and Treatment of Inflammatory Conditions’, will research compositions and methods for modulating type 2 diverse and/or type 1 invariant NKT cells in the prevention and treatment of inflammatory conditions.
Marc Hertz, chief executive officer of GRI Bio, commented: “We believe our highly differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases represents a compelling opportunity to address unmet medical needs for patients.”
GRI Bio seeks to develop treatments for these respective diseases by targeting the activity of NKT cells, which are key regulators in the inflammatory cascade, to interrupt progression of disease and restore the immune system to homeostasis.
The company’s lead programme, GRI-0621, is being evaluated as a treatment of idiopathic pulmonary fibrosis (IPF). Topline results from the phase 2a trial are expected later in 2025.
Ella Day
2/4/2025
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
